Demand Led Supply Model To Improve Clinical Trial Supply Chains To Be Discussed By Catalent Expert

Somerset, N.J. – September 24, 2015 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products and a leader in global clinical supply services, today announced that Dr. Paul Ingram, Global Director, Strategic Business Development will be presenting at the upcoming 3rd Annual Clinical Trials Supply Chain Conference, to be held at the Novotel Berlin am Tiergarten Hotel, Germany, on September 29th – 30th, 2015.

Dr. Ingram’s presentation, on Tuesday, September 29th at 11.45 a.m., is entitled “Demand Led Supply: Reducing Stock-Out Risk and Improving Supply Chain Predictability”, and will discuss how the traditional supply-led approach has historically required longer lead times, and is sensitive to variability even with the use of advanced forecasting tools. This can result in excess inventory or, worse still, drug shortages and the potential for patients to be put at risk when treatments aren’t available. Dr. Ingram will also discuss the impact of the demand led supply (DLS) model on patients, clinical sites, clinical personnel and study sponsors; the advantages of using a DLS model versus a traditional supply-led approach; strategies to successfully implement DLS; and when a hybrid DLS model may be appropriate for clinical studies.

Dr. Ingram’s 25 year career has focused on Medical Device and Pharmaceutical Research and Development. He obtained his Ph.D. in Pharmaceutical Development from Strathclyde University, Scotland, and has over 15 years of experience in clinical supplies, working both in Phase I Units and trial supplies service companies including Quintiles (Aptuit), Fisher Clinical and Catalent.  

For more information on the Clinical Trials Supply Chain Conference, visit: and to arrange a meeting with Dr. Ingram, contact Richard Kerns at NEPR- .

About Catalent 

Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit

More products. Better treatments. Reliably supplied.™